Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok(Cornell University), Mario Sznol(Yale University), Margaret K. Callahan(Cornell University), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Matthew M. Burke(Yale New Haven Hospital), H. David Inzunza(Memorial Sloan Kettering Cancer Center), RuthAnn Gordon(Memorial Sloan Kettering Cancer Center), Israel Lowy(Bristol-Myers Squibb (Germany)), Blessing Agunwamba(Memorial Sloan Kettering Cancer Center), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Alan J. Korman(Bristol-Myers Squibb (Germany)), Kathleen Reed(Yale New Haven Hospital), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Neil H. Segal(Kettering University), William F. Feely(Memorial Sloan Kettering Cancer Center), Naiyer A. Rizvi(Synthego (United States)), Anne Caldwell(Yale New Haven Hospital), Stephanie Anne Kronenberg(Memorial Sloan Kettering Cancer Center), Xiaoling Zhang(Memorial Sloan Kettering Cancer Center), Christine E. Horak(Bristol-Myers Squibb (United States)), Ashok Gupta, Harriet M. Kluger(Yale Cancer Center), Quan Hong(Gilead Sciences (United States)), Charlotte E. Ariyan(Memorial Sloan Kettering Cancer Center)
Cited by 4,221
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k